Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 ...
Neoadjuvant immunotherapy could considerably improve long-term outcomes and quality of life for patients with desmoplastic melanoma, according to prospective study results.Nearly three-quarters of ...
Access to modern HER2-targeted therapy and early diagnosis are required to improve outcomes of patients with HER2-positive breast cancer worldwide. We conducted this study to determine the factors ...
Neoadjuvant, but not adjuvant, chemoimmunotherapy significantly improved key outcomes in certain patients with early breast cancer, according to a meta-analysis involving more than 5,000 patients.
Clinical research presented at the European Society for Medical Oncology Congress 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and ...
Tyvyt plus CRT achieved a 60% pCR rate, outperforming Tyvyt plus chemotherapy (13%) and CRT alone (47.3%). Neoadjuvant Tyvyt plus CRT may become a new standard of care for resectable, locally advanced ...
Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical Data Patients aged 18 years and older ...
Use of nivolumab before chemotherapy was no better than concurrent treatment in early triple-negative breast cancer. De-escalated treatment produced "clinically relevant" pathologic complete responses ...
In a phase 2 trial of nonurothelial MIBC, half of patients receiving neoadjuvant chemoimmunotherapy showed no residual cancer at the time of surgery. The single-center, phase 2 trial included 17 ...
NEW ORLEANS — Results from the I-SPY 2 trial show that a new presurgery (neoadjuvant) combination of trastuzumab emtansine (T-DM1; Kadcyla, Genentech, Inc) and pertuzumab (Perjeta, Genentech, Inc) — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results